Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412958 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
A Phase 2 study of Vitrectomy, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT00412958: Completed Phase 2 study of Vitrectomy, sponsored by ThromboGenics.
NCT00412958 is a Phase 2 study of Vitrectomy that has completed, run by ThromboGenics. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00412958, a Phase 2 study of Vitrectomy, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
Primary Outcome
The primary efficacy endpoint was the proportion of patients achieving total PVD without creation of an anatomical defect (ie, retinal hole, retinal detachment) based on surgeon visualization at the beginning of vitrectomy prior to suction or any other mechanical intervention.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ocriplasmin 25µg
- DRUG Ocriplasmin 75µg
- DRUG Ocriplasmin 125µg
Study Locations (20)
California
- VMR Institute - Huntington Beach
- Jules Stein Eye Institute/UCLA - Los Angeles
- Retinal Consultants of San Diego - Poway
- Retinal Consultants Medical Group - Sacramento
Florida
- National Ophtlamic Research Institute - Fort Meyers
- Center for Retina and Macular Disease - Winter Haven
New York
- Columbia University - Harkness Eye Institute - New York
- Retina Vitreous Surgeons of Central NY - New York
Texas
- Vitreoretinal Consultants - Houston
- Valley Retina Institute, P.A. - McAllen
Arizona
- Retina Centers, P.C. - Tucson
Illinois
- Rush University Med. Ctr - Chicago
Massachusetts
- Mailing add: New England Eye Center - Tufts - Boston
Michigan
- Associated Retinal Consultants, P.C. - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00412958 record still lists
NCT00412958 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Vitrectomy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00412958 names 20 study sites across 14 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00412958 about?
NCT00412958 is a clinical study titled "A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)". A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
What is the current status of trial NCT00412958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2006-12. Estimated completion is 2008-10.
What conditions does trial NCT00412958 study?
This clinical trial studies the following conditions: Vitrectomy.
What interventions are being tested in trial NCT00412958?
The interventions under investigation include: Placebo (DRUG), Ocriplasmin 25µg (DRUG), Ocriplasmin 75µg (DRUG), Ocriplasmin 125µg (DRUG).
Who is sponsoring clinical trial NCT00412958?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00412958 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitrectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00412958's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia